Researchers Identify A New Vaccine Candidate for Chikungunya Virus

A new method of vaccine creation for Chikungunya virus (CHIKV) using a technique called large scale random codon re-encoding was developed by researchers.

A new method of vaccine creation for Chikungunya virus (CHIKV) using a technique called large scale random codon re-encoding was developed by researchers. This method has helped them modify nucleic acid composition of the virus without changing encoded viral proteins.

Using this approach, a group from the UMR_D 190, Emerging viruses Department in Marseille, France in collaboration with the University of Sydney, Australia, showed that the engineered viruses exhibit a stable phenotype with a significantly decreased viral fitness (i.e., replication capacity), making it a new vaccine candidate for the emerging viral disease.

Chikungunya - Causes, Symptoms, Diagnosis, Treatment. FAQs
Chikungunya is a viral disease spread by mosquito bites; it causes fever, severe joint pain and rash on the body. Chikungunya occurs in Africa, Asia and the Indian sub continent.

When the large-scale codon re-encoding method was applied by Antoine Nougairede and his colleagues to poliovirus and Influenza A virus, it resulted in a live but attenuated virus that had significant reduction of viral fitness.

This study demonstrates that a random approach reduced the replicative fitness of CHIKV in both primate and arthropod cells.

The strategy also prevented the reversion of the attenuated phenotype by mutation or recombination, thus reducing the possibility that the newly created virus strain could evolve back to the pathogenic version.

Chikungunya Make a Comeback in Kolkata
A man from a south Kolkata neighbourhood tested positive for the chikungunya virus earlier this week.

The findings suggest that large-scale codon re-encoding can provide a strong basis for the rapid design of next-generation viral vaccines against emerging viral pathogens, as soon as their genome sequence has been determined.

It represents another route to vaccine development as it intrinsically alleviates the likelihood of novel pathogenic properties of the designed live vaccine, and allows modulation of the amount of reduced fitness by altering the terms and degree of the genetic re-encoding.

Kochi To Conduct Campaigns Against Chikungunya
The Kochi Corporation has announced that it will be conducting a drive against chikungunya

Thus, this strategy potentially allows for the generic development of live attenuated vaccines against many new viral pathogens, with reduced costs and the potential single dose induction of long-term immunity.

This report has been published in the Open Access journal, PLOS Pathogens.

No Chikungunya Deaths In Kerala
The Kerala Health Department today clarified that so far no chikungunya deaths were reported in the state.

Source-ANI